Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazinecarboxamide SCHEMBL1464078 | 0.87 | MEN1 (0.46) | MAPTHSP90AA1HSP90AB1LMNAMEN1 | |
| SCHEMBL16717955 | 0.82 | MAPT (0.59) | MAPTHSP90AA1HSP90AB1LMNAMEN1 | |
| SCHEMBL18073590 | 0.81 | MAPT (0.54) | MAPTHSP90AA1HSP90AB1LMNAMEN1 | |
| SCHEMBL6439644 | 0.80 | MAPT (0.54) | MAPTHSP90AA1HSP90AB1LMNAMEN1 | |
| SCHEMBL16300444 | 0.80 | MAPT (0.54) | MAPTHSP90AA1HSP90AB1LMNAMEN1 | |
| SCHEMBL20669685 | 0.79 | MAPT (0.52) | MAPTHSP90AA1HSP90AB1LMNAMEN1 | |
| SCHEMBL23742574 | 0.77 | MAPT (0.50) | MAPTHSP90AA1HSP90AB1LMNAMEN1 | |
| SCHEMBL24192688 | 0.76 | MAPT (0.48) | MAPTHSP90AA1HSP90AB1LMNAMEN1 | |
| SCHEMBL3341425 | 0.76 | MAPT (0.71) | MAPTHSP90AA1HSP90AB1LMNAMEN1 | |
| SCHEMBL18801067 | 0.75 | MAPT (0.59) | MAPTHSP90AA1HSP90AB1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | claimed |
| WO-2022012622-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
| US-20160264558-A1 | FLUOROGENIC PROTECTING GROUP | ISIS INNOVATION (GB) | 2016-09-15 | — | — | US | disclosed |
| CN-102264723-B | Dihydropyridone amides as p2x7 modulators | HOFFMANN LA ROCHE | 2014-12-10 | — | — | CN | disclosed |
| US-8871760-B2 | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871760-B2 | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871760-B2 | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| WO-2011033055-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011033055-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110071143-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-03-24 | — | — | US | disclosed |
| US-20110071143-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-03-24 | — | — | US | disclosed |
| WO-2010072597-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072597-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264558-A1 | FLUOROGENIC PROTECTING GROUP | HIF1AN, HIF1A, HYOU1 | MAPT 4138/4885HSP90AA1 769/4885HSP90AB1 394/4885 |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | MAPT 1035/4885HSP90AA1 3310/4885HSP90AB1 3058/4885 |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX3, P2RX1 | MAPT 2895/4885HSP90AA1 2713/4885HSP90AB1 2594/4885 |
| US-20110071143-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | P2RX3, P2RX7, P2RX1 | MAPT 3294/4885HSP90AA1 3314/4885HSP90AB1 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.